MRCF invests in antibiotics start-up Auspherix

Auspherix, an early stage anti-infectives company has launched with AU$1 million in start-up financing from Australia’s Medical Research Commercialisation Fund. Auspherix will in-license intellectual property from the ithree institute at the University of Technology Sydney, emerging from research led by Professor Ian Charles, director of the ithree institute together with Dr Dagmar Alber, ithree Senior Research Fellow.

North AmericaUSBriefs